News | January 24, 2025
Alivus Life Sciences delivers 12% revenue growth
EBITDA margins expand to 31.3%
EBITDA margins expand to 31.3%
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
This certification will open new markets for the Kwality Pharma
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Subscribe To Our Newsletter & Stay Updated
